Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
Since the introduction of bisphosphonates to treat diseases that affect remodelling of bone, increasing numbers of patients with bisphosphonate-related osteonecrosis of the jaws have been reported; the number is currently unknown. Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases. We report a case of osteonecrosis that was induced by anti-RANKL therapy. To our knowledge this is the first case to have been induced by these agents.
Taylor
K H
KH
Pinderfields General Hospital, Wakefield, West Yorkshire, United Kingdom. k.h.taylor@leeds.ac.uk
Middlefell
L S
LS
Mizen
K D
KD
D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002277:Carcinoma / Q000188:drug therapy; D002710:Chlorhexidine / Q000627:therapeutic use; D000069448:Denosumab; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced*; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use; D010020:Osteonecrosis / Q000139:chemically induced*; D053245:RANK Ligand / Q000009:adverse effects*; D014945:Wound Healing / Q000502:physiology
D000891:Anti-Infective Agents, Local; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009067:Mouthwashes; D053245:RANK Ligand; D000069448:Denosumab; D002710:Chlorhexidine